New combo therapy shows promise for rectal cancer patients

This study tested a treatment plan for people with advanced rectal cancer that had not spread. First, patients received standard chemotherapy and radiation for several weeks. Then, they received three doses of an immunotherapy drug called Sintilimab. The goal was to see if this combination could completely eliminate the tumor before surgery, potentially allowing more patients to avoid a permanent colostomy. The study involved 30 participants and was completed.